Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Withdrawn × Neuroendocrine Tumors × Clear all

Phase

Phase 2 6 Phase 1/2 3 Phase 1 2 Phase NA 1 Phase EARLY_PHASE1 1 Phase 3 1

Status

Completed 13 Recruiting 9 Active not recruiting 5 Terminated 2 Withdrawn 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Breast Neoplasms 23 Neoplasms 17 Prostatic Neoplasms 14 Carcinoma, Non-Small-Cell Lung 12 Carcinoma, Hepatocellular 10 Head and Neck Neoplasms 8 Urinary Bladder Neoplasms 7 Pain 7 Ovarian Neoplasms 7 Leukemia, Myeloid, Acute 7 Squamous Cell Carcinoma of Head and Neck 6 Neoplasm Metastasis 6 Lung Neoplasms 6 Lymphoma, Follicular 5 Leukemia 5 Brain Neoplasms 5 Uterine Cervical Neoplasms 4 Stomach Neoplasms 4 Small Cell Lung Carcinoma 4 Precursor Cell Lymphoblastic Leukemia-Lymphoma 4 Lymphoma, Non-Hodgkin 4 Lymphoma 4 Carcinoma 4 Urogenital Neoplasms 3 Papillomavirus Infections 3 Pancreatic Neoplasms 3 Non-Muscle Invasive Bladder Neoplasms 3 Melanoma 3 Lymphoma, B-Cell, Marginal Zone 3 Leukemia, Lymphocytic, Chronic, B-Cell 3

Interventions

lutetium Lu 177 dotatate 1 Introns 1 177Lu-octreotate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01860742 2016-04-05

CASTOR

Jules Bordet Institute

Phase 3 Withdrawn

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡